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Abstract: Background and objectives: Patients with atrial fibrillation (AF) reportedly have a much
higher risk of death due to stroke. Faced with this heavy burden, it remains unclear if the Chinese
herbal medicines (CHMs), the most common form complementary and alternative medicine, can
lower the risk of stroke for them. This study aimed to evaluate the association of CHMs use with
stroke risk among them. Materials and Methods: From a nationwide database, 11,456 AF patients aged
≧ 20 years between 1998 and 2007 were identified. Afterwards, we enrolled 2670 CHMs users and
randomly selected 2670 non‐CHMs users using the propensity score method. The occurrence of
stroke was recorded until the end of 2012. Results: Within the follow‐up period, 671 CHMs users
and 900 non‐CHMs users developed stroke, with incidence rates of 33.02 and 45.46 per 1000 person‐
years, respectively. CHMs use was associated with a 30% lower stroke risk, especially for those
receiving CHMs for over two years. Conclusions: The findings of the present study suggest that
adding CHMs to conventional therapy could decrease subsequent stroke risk for AF patients. It is
also suggested that prospective randomized trials are needed to further clarify if the detected
association revealed in this study supports a causal link, and to identify the specific CHMs that may
be beneficial to AF patients.
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1. Introduction
Atrial fibrillation (AF) is a common irregular cardiac rhythm disorder [1], which has been proven
to exacerbate the risk for several cardiac and cerebral vascular diseases, especially strokes [2,3]. A
recent report further indicated that about 15% of stroke events in the United States are attributable to
AF [4]. Once AF patients suffer from concomitant stroke, their chance of dying doubles compared to
those who do not have a stroke [5]. Though warfarin is the commonly used oral anticoagulant for
reducing the incidence of thromboembolism for AF patients [6,7], the prescription of warfarin has to
be cautious, as the dosage is usually influenced by foods and other drugs, thus provoking the risk of
bleeding and stroke [8]. As such, investigating the alternative treatments with fewer side effects is of
great significance for disease management towards AF.
Recently, Chinese herbal medicines (CHMs) have been used often to improve well‐being for
patients with chronic diseases, especially in patients with AF [9]. Based on traditional Chinese
medicine theory, the blood‐invigorating and stasis‐removing (BISR) herbal products are commonly
used to prevent or treat stroke [10]. These medications include Dan Shen Decoction, Bu Yang Huan
Wu Tang, and Shu Jing Huo Xue Tang, all of which may slow the heart rate or inhibit the platelet
aggregation, and as such, enhance cardiovascular health [9,11].
Though these medications have attracted attention for some time, studies evaluating their
efficacy have still yielded inconsistent findings. Some recent studies showed that CHMs combined
with conventional therapy may contribute to positive benefits in the management of stroke [9,12]. In
contrast, a recent review of 54 studies indicated that the integration of CHMs and warfarin therapy
would increase the risk of bleeding due to the exacerbation of the anticoagulant effect [13], implying
that the combined use of CHMs and warfarin should be allocated much attention for AF patients.
Following a detailed literature review, we observe that no large‐scale studies have been
conducted to adequately examine the influence of concomitant use of CHMs on the following stroke
risk, especially in AF patients. Thus, this population‐based study aimed to compare the risk of stroke
among AF patients who received CHMs together with warfarin with those patients who received
warfarin treatment only.
2. Materials and Methods
2.1. Data Source
For this study, we used a publicly released cohort dataset from the Longitudinal Health
Insurance Database (LHID). The LHID, a sub‐dataset of the National Health Insurance (NHI)
program made up of one million randomly sampled people who were alive in 2000, is a collection of
all medical records of these individuals from 1996 to 2012. Constructed using a multistage stratified
systematic sampling method, it is a representative sample, in both sex and age, of these one million
insured individuals and the general population of Taiwan [14]. This database contains all NHI
enrollment files, claims data and a prescription drugs registry, and provides comprehensive
utilization information for the persons covered by the NHI. The current study was conducted in
accordance with the Helsinki Declaration and was approved by the Institutional Review Board and
Ethics Committee of Buddhist Dalin Tzu Chi Hospital, Taiwan (No. B10004021‐2) on 31 August 2015,
which waived the requirement for informed consent.
2.2. Study Subjects and Variables
In this work, to be designated as having a certain disease, the subject had to have a
corresponding code by the International Classification of Disease, Ninth Revision, Clinical
Modification (ICD‐9‐CM) in the diagnosis field. We recruited the subjects ≥ 20 years of age who
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sought ambulatory health care services due to AF (ICD‐9‐CM code: 427.31 or 427.89) in 1998 and 2007.
Cases were classified as being AF if they had at least one admission code for AF, or three or more
outpatient visits codes during the study period including the prescription of warfarin medication for
a period of three months (n = 14,636). To establish a temporal link between AF and stroke, we omitted
those who were followed for less than one year after the onset of AF (n = 157), and those with a
diagnosis of stroke prior to the first AF onset (n = 3023). The stroke event was identified by the
catastrophic illness registry. Only those patients with catastrophic illness certification due to stroke
(ICD‐9‐CM code 430‐438) were recruited. In Taiwan, insured residents with major diseases (e.g.,
cancer, autoimmune diseases, chronic mental diseases end‐stage renal failure) can apply for a
catastrophic illness certificate for exemption from co‐payment. After this filtering process, a total of
11,456 AF subjects were identified.
In Taiwan, only certified Chinese medicine physicians are entitled to prescribe CHMs.
Accordingly, we used the drug days of Chinese herbal products to verify the CHM exposure of each
AF patient. Among them, those who received CHMs for more than 30 days were considered CHM
users, whereas those treated for 30 days or less were considered non‐CHM users [15]. Based on this
procedure, 8727 cases were designated as CHM users. A comparison cohort was randomly selected
from the remaining insured AF patients who were not CHM users. For each patient receiving CHM
treatment, a patient with no CHM treatment was selected, using 1:1 matching based on a propensity
score. The propensity score was calculated using logistic regression on the basis of patient
demographics and baseline comorbidities at enrollment. Ultimately, an equal number of subjects
were enrolled in the CHM and non‐CHM groups (Figure 1). The index date for AF subjects who were
classified as non‐CHM users was defined as the date of the first AF diagnosis, whereas the index date
for AF cases who received CHMs was defined as the first date of receiving CHMs. The end date of
the follow‐up period for both groups was defined as the earliest of a diagnosis of stroke, withdrawal
from the insurance program, or the date of December 31, 2012. The incidence rate of stroke was
defined as number of events divided by the person‐time at risk.
14,636 newly diagnosed subjects with AF ≥ 20 years of age
treated with warfarin between 1998 and 2007

Subject excluded:
(1) 3023 patients who had a stroke before the date of
first AF diagnosis
(2) 157 patients who died or withdrew from the NHI
program within one year following AF

8727 non‐CHMs users

2729 CHMs users

Propensity score matching at a 1:1 ratio by
demographic data and coexisting medical conditions

900 stroke events occurred in

671 stroke cases occurred in

2670 non‐CHMs users

2670 CHMs users

Medicina 2020, 56, 282

4 of 12

Figure 1. Flow chart of subject inclusion. AF: Atrial Fibrillation, CHM: Chinese herbal medicines

2.3. Covariate Assessment
Sociodemographic factors in this study included patient age, gender, income (for estimating
insurance payments), and urbanization level of each subject’s residential area. The subjects’ monthly
incomes were stratified into three levels: New Taiwan Dollars (NTDs) ≤ 17,880; 17,881–43,900; and ≥
43,901. Urbanization levels were divided into urban (levels 1–2), suburban (levels 3–4) and rural
(levels 5–7) areas. Level 1 refers to the “most urbanized” communities and level 7 refers to the “least
urbanized” communities [16]. Baseline comorbidities for each subject included hypertension (ICD‐9‐
CM 401–405), diabetes (ICD‐9‐CM 250), ischemic heart disease (ICD‐9‐CM 410–414, 443.89, 443.9 and
444), hyperlipidemia (ICD‐9‐CM 272), and congestive heart failure (ICD‐9‐CM 428, 402.01, 402.11,
402.91, 404.01, 404.11 and 404.91). These comorbidities were based on data in the medical records one
year prior to the diagnosis of AF.
2.4. Statistical Analysis
We employed the χ2 test and Student’s t‐test to examine the baseline differences in
sociodemographic characteristics and comorbidities between subjects with and without receiving
CHMs. The incidence rate of stroke was presented with the number of cases per 1000 person‐years
(PYs). The Cox proportional hazards regression analysis was then applied to compute the hazard
ratio (HR) with 95% confidence interval (CI) of stroke risk in association with CHM usage. To
robustly explore the association of CHM therapy and the risk of stroke, we divided the CHM users
into three subgroups: those with used CHMs for 30–365 days, those who used CHMs for 366–730
days and those who used CHMs for more than 730 days. Kaplan–Meier failure estimates of stroke
risk were plotted and the differences between the three groups were examined using the log‐rank
test. The proportional‐hazards assumption was verified using plots of log (‐log (survival function)
vs. log (time), and Schoenfeld residuals vs. time. All analyses were conducted using SAS version 9.3
(SAS Institute Inc., Cary, NC, USA). Values of p < 0.05 were considered to indicate statistical
significance.
3. Results
The CHM user and non‐CHM user cohorts were each comprised of 2670 patients. Table 1 shows
the pertinent characteristics of the two groups, including distributions of age, sex, monthly income,
residential area and comorbidities, indicating that the two groups were comparable in all
characteristics.
Table 1. Subject demographic data and comorbidities.
Variables
Age
Mean (standard deviation)
Sex
Female
Male
Monthly income
Low
Median
High
Residential area
Urban
Suburban
Rural
Comorbidity
Hypertension
Diabetes mellitus
Hyperlipidemia

CHMs Non‐Users
n = 2670 (%)

CHMs Users
n = 2670 (%)

p
0.32

58.03 (15.88)

58.46 (15.18)

1377 (48.4)
1293 (51.6)

1371 (51.3)
1299 (48.7)

1193 (44.7)
1386 (51.9)
91 (3.4)

1176 (44.0)
1384 (51.8)
110 (4.1)

1372 (51.4)
404 (15.1)
894 (33.5)

1351 (50.6)
447 (16.7)
872 (32.7)

1228 (46.0)
372 (13.9)
364 (13.6)

1208 (45.2)
405 (15.2)
342 (12.8)

0.87

0.38

0.27

0.58
0.20
0.37
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Ischemic heart disease
Congestive heart failure

959 (35.9)
48 (1.8)

990 (37.1)
51 (1.9)

0.38
0.76

Among the sampled AF patients, 1571 first episodes of stroke were identified; 900 were among
the non‐CHM users and 671 among the CHM users during the follow‐up periods of 19,799.80 and
20,320.77 person‐years (PYs), respectively. The incidence of stroke was lower among CHM users than
among non‐CHM users (33.02 vs. 45.46, respectively, per 1000 PYs), with an adjusted HR (95% CI) of
0.70 (0.63–0.77) (Table 2). Of note, those who used CHMs for more than 730 days had a 68% decreased
risk of stroke (95% CI: 0.20–0.51) versus non‐users. Based on the Kaplan–Meier survival curve and
log‐rank test results, the data also supported a statistically significant difference in the survival rate
free from stroke across the three groups of users during the follow‐up period. Those receiving CHMs
for more than two years had a significantly lower incidence rate of stroke than those not receiving
CHMs (p < 0.001) (Figure 2).
Table 2. Risk of stroke for AF patients with and without CHM use.
Crude HR

Adjusted HR *

(95% CI)

(95% CI)

45.46

1.00

1

20,320.77

33.02

0.73 (0.65–0.78)

0.70 (0.63–0.77)

607

16,628.21

36.50423

0.78 (0.71–0.86)

0.77 (0.68–0.84)

46

2353.39

19.54627

0.43 (0.32–0.57)

0.47 (0.35–0.63)

18

1339.16

13.44126

0.30 (0.19–0.48)

0.32 (0.20–0.51)

Event

PYs

Incidence

Non‐CHMs users

900

19,799.80

CHMs users

671

CHMs use within
31–365 days
CHMs use for 366–
730 days
CHMs use for
more than 730 days

Incidence rate is per 1000 person‐years.; * Model adjusted for age, sex, urbanization level, monthly
income, and comorbidities. HR: Hazard Ratio, CI: confidence interval
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Figure 2. Cumulative incidence of stroke in AF patients with and without receiving CHM treatment
during the study period (Log‐rank test, p < 0.001).
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The most commonly prescribed herbal products for AF patients were reported in Table 3. Among them, with the exception of Bu Yang Huan Wu Tang
(BYHWT) and Fu Fang Dan Shen Pian (FFDSP), the other herbal products were found to be related to a significantly lower stroke risk.
Table 3. Risk of stroke in relation to the commonly used CHM products.
The Commonly
Ingredient of Generic Name

Function of CHMs

Crude HR

Adjusted HR

(95% CI)

(95% CI) *

0.78

0.76

(0.57–1.07)

(0.55–1.05)

0.67

0.66

(0.60–0.76)

(0.60–0.75)

0.92

0.91

(0.71–1.12)

(0.72–1.15)

0.35

0.34

(0.12–0.84)

(0.13–0.82)

Frequency

Prescribed CHMs
Anti‐atherosclerosis by
dilating the cerebral vessels,
Fu Fang Dan Shen
Pian (FFDSP)

Dan Shen (Salvia miltiorrhiza Bunge), San Qi (Panax notoginseng (Burkill) F.H.Chen) and Bing Pian
(Dryobalanops aromatica Gaertn. f.)

inhibiting the aggregation of
platelets, activating

2563

circulation, dispersing blood
stasis
Dang Gui (Angelica sinensis Oliv. Diels), Gan Cao (Radix Liquiritiae Fisch), Bai Shao (Paeonia
lactiflora Pallas), Sheng Di Huang (Radix Rehmanniae Recens), Cang Zhu (Atractylodes lancea
Anti‐coagulation effect, anti‐
Shu Jing Hwo

(Thunb.) DC.), Niu Xi (Achyranthes bidentata Blumb), Chen Pi (Citrus reticulata Blanco), Wei Ling

Shiee Tang

Xian(Clematis chinensis Osbeck.), Fanɡ Ji (Stephania tetrandra S. Moore), Qiang Huo (Notopterygium

(SJHST)

incisum Ting ex H. T. Chang), Bai Zhi (Angelicae Dahuricae Radix), Lonɡ Dan Cao (Gentiana scabra

hypersensitivity effects,
4518
increasing blood circulation
and relieving pain
Bge.), Chuan Xiong (Ligusticum striatum DC.), Tao Ren (Prunus persica L. Batsch), Fu Ling (Poria
cocos (Schw.) Wolf) and Sheng Jiang (Zingiber officinale Rosc.)

Bu Yang Huan Wu

Huan Qi (Astragalus membranaceus Fisch.), Dang Gui Tail (Angelica sinensis Oliv. Diels), Chi Shao

Anti‐coagulation, removing

Yao (Paeonia lactiflora Pall. or Paeonia veitchii Lynch), Chuan Xiong (Ligusticum striatum DC.), Tao

blood stasis, neuroprotective
2751

Tang (BYHWT)

Ren (Prunus persica L. Batsch), Hong Hua (Carthamus tinctorius L.) and Di Long (Pheretima

and neurogenesis‐promoting

aspergillum (Perrier) or Allolobophora caliginosa (Savigny) Trapezoides (Ant. Duges))

effects

Chi Shao Yao (Paeonia lactiflora Pall. or Paeonia veitchii Lynch), Chuan Xiong (Ligusticum striatum

Removing blood stasis,

DC.), Tao Ren (Prunus persica L. Batsch), Hong Hua (Carthamus tinctorius L.), She Xiang (Moschus

neuroprotective effects by

Tong Qiao Huo
Xue Tang
(TQHXT)

4735
berezovskii Flerov), Cong (Alium fistulsum L.), Sheng Jiang (Zingiber officinale Rosc.) and Da Zao

inhibiting inflammatory

(Ziziphus jujuba Mill.)

responses and apoptosis
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Chai Hu (Radix Bupleuri), Dang Gui (Angelica sinensis Oliv. Diels), Sheng Di Huang (Radix
Removing blood stasis,
Rehmanniae Recens), Chi Shao Yao (Paeonia lactiflora Pall. or Paeonia veitchii Lynch), Hong Hua
Xue Fu Zhu Yu
Tang (XFZYT)

neuroprotective effects by
(Carthamus tinctorius L.), Tao Ren (Prunus persica L. Batsch), Zhi Qiao (Fructus Aurantii Immaturus),

inhibiting inflammatory

6190

0.66

0.67

(0.57–0.76)

(0.58–0.77)

0.59

0.58

(0.35–0.93)

(0.35–0.94)

0.69

0.68

(0.51–0.92)

(0.50–0.92)

0.55

0.54

(0.35–0.86)

(0.35–0.85)

0.45

0.42

(0.31–0.67)

(0.30–0.63)

0.68

0.66

(0.56–0.82)

(0.56–0.81)

Gan Cao (Radix Liquiritiae Fisch), Chuan Xiong (Ligusticum striatum DC.), Niu Xi (Achyranthes
bidentata Blumb), and Jie Geng (Platycodon grandiflorum (Jaoq.) A.DC.)

responses and apoptosis

Dang Gui (Angelica sinensis Oliv. Diels), Chuan Xiong (Ligusticum striatum DC.), Chi Shao Yao

Ge Xia Zhu Yu

(Paeonia lactiflora Pall. or Paeonia veitchii Lynch), Tao Ren (Prunus persica L. Batsch), Wu Ling Zhi

Activating blood to dispel

(Trogopterus xanthippes Milne‐Edwards), Hong Hua (Carthamus tinctorius L.), Mu Dan Pi (Paeonia

stasis, Invigorating qi
5273

Tang (GXZYT)

suffruticosa Andr.) and Wu Yao (Lindera aggregata (Sims) Kosterm.), Yan Hu Suo (Corydalis

movement and relieving

yanhusuo W. T. Wang), Gan Cao (Radix Liquiritiae Fisch), Xiang Fu (Cyperus rotundus Linn) and

pain

Zhi Ke (Citrus aurantium L.)
Dang Gui (Angelica sinensis Oliv. Diels), Da Huang (Rheum rhabarbarum L.), Tao Ren (Prunus

Invigorating blood

persica L. Batsch), and Chai Hu (B.chinense DC. Or B.scorzonerifolium Willd), Hong Hua (Carthamus

circulation and dispelling

tinctorius L.), Tian Hua Fen (Trichosanthis Kirlowii Radix) and Gan Cao (Radix Liquiritiae Fisch)

blood stasis

Fu Yuan Huo Xue
6140

Tang (FYHXT)
Invigorating blood
Tao He Cheng Qi

Da Huang (Rheum rhabarbarum L.), Tao Ren (Prunus persica L. Batsch), Gui Zhi (Ramulus

circulation and eliminating
4494

Tang (THCQT)

Cinnamomi Cassiae), Mang Xiao (Natrii Sulfas) and Gan Cao (Radix Liquiritiae Fisch)

distension and spasmodic
pain

Tao Hong Si Wu

Shu Di Huang (Rehmannia glutinosa Liboschitz), Bai Shao (Paeonia lactiflora Pallas), Dang Gui

Promoting blood circulation

(Angelica sinensis (Oliv.) Diels), Chuan Xiong (Ligusticum chuanxiong Hort.), Tao Ren (Prunus
Tang (THSWT)

7877
and neuroprotective activity

persica (L.) Batsch.), and Hong Hua (Carthamus tinctorius L)
Qin Jiao (Radix Gentianae Macrophyllae), Dang Gui (Angelica sinensis Oliv. Diels), Chuan Xiong
(Ligusticum striatum DC.), Tao Ren (Prunus persica L. Batsch), Hong Hua (Carthamus tinctorius L.),
Shen Tong Zhu Yu

Wu Ling Zhi (Trogopterus xanthippes Milne‐Edwards), Niu Xi (Achyranthes bidentata Blumb), Qiang

Removing blood stasis and
5934

Tang (STZYT)

Huo (Notopterygium incisum Ting ex H. T. Chang), Mo Yao (Commiphora myrrha Engl), Xiang Fu

anti‐inflammatory effect

(Cyperus rotundus Linn), Di Long (Pheretima aspergillum (Perrier) or Allolobophora caliginosa
(Savigny) Trapezoides (Ant. Duges)) and Gan Cao (Radix Liquiritiae Fisch)

* Model adjusted for age, sex, urbanization level, monthly income, and comorbidities.

Medicina 2020, 56, 282

9 of 12

4. Discussion
This is the first large nationwide population‐based cohort study to compare the stroke risk in AF
patients who were prescribed warfarin with or without the use of CHMs. This work yielded two
major findings. First, the stroke risk was significantly lower in AF patients who received CHMs as
compared to those who did not receive CHMs, especially for those receiving CHM treatment for more
than two years. Second, the commonly prescribed herbal products, such as Shu Jing Hwo Shiee Tang
(SJHST), Tong Qiao Huo Xue Tang (TQHXT), Xue Fu Zhu Yu Tang (XFZYT), Ge Xia Zhu Yu Tang
(GXZYT), Fu Yuan Huo Xue Tang (FYHXT), Tao He Cheng Qi Tang (THCQT), Tao Hong Si Wu Tang
(THSWT) and Shen Tong Zhu Yu Tang (STZYT), were found to be associated with a decreased risk
of stroke.
Results of this long‐term follow‐up study found that AF patients who received CHMs exhibited
a 30% decreased risk of stroke as compared to those who did not receive CHMs, echoing prior studies
[9,12]. It could be inferred that the commonly used CHMs such as Danshen dripping pills or XFZYT
may lessen the risk of stroke by the inhibition of platelet aggregation, free radical scavenging, and
anti‐inflammatory and neuroprotective properties. Nevertheless, our findings are inconsistent with
a former report, which found that the concurrent use of CHMs may increase the bleeding risk for AF
patients taking warfarin [17]. These conflicting findings may be attributed to methodological
differences between the two studies. Saw and colleagues used a self‐administered questionnaire to
obtain information regarding the use of CHMs, but the method used may be influenced by recall bias
[17]. Furthermore, the cross‐sectional design employed in their study does not allow for any inference
about any cause‐and‐effect relationships between the tested variables.
An additional contribution of this cohort study was the list of herb products that were related to
the lower risk of stroke. For example, we noted that the use of THSWT was related to decreased
stroke risk. A previous marine model indicated that this formula could reduce the risk of cerebral
ischemia via suppressing caspase‐3 and inducible nitric oxide synthase expression [18]. Additionally,
the other commonly used CHMs for treating AF, such as TQHXT, XFZYT, GXZYT, and STZYT, were
found to be associated with a lower risk of stroke, echoing prior studies [11,19]. Among these herbal
formulae, Dang Gui (Angelica sinensis Oliv. Diels), Chuan Xiong (Ligusticum striatum DC. stem and
root), Tao Ren (Prunus persica L. Batsch), and Hong Hua (Carthamus tinctorius L. flower) are the major
ingredients that were proven to have BISR effects via the inhabitation of platelet aggregation and
inflammatory responses [11,20]. In practice, the use of these formulae depends on the location of
stasis. The prescription of TQHXT focuses on the area above the neck [21], and XFZYT focuses on the
chest [22,23]. As for GXZYT, it is commonly used to treat the stasis occurring between the diaphragm
and lower abdomen [24], and STZYT is utilized to remove the stasis on the limbs and musculoskeletal
system [25].
This study also revealed that the use of FYHXT and THCQT was associated with a reduced risk
of stroke. Tao Ren and Da Huang (Rheum rhabarbarum L. stalks) are the major ingredients of these
formulae, and both have been proven to have anti‐blood stasis effects [11]. In addition, SJHST can
invigorate the blood, relax the blood vessels, and treat blood stagnation resulting from wind‐cold‐
dampness, thereby decreasing the risk of cerebrovascular disease [10,26,27]. Alternatively, the failure
to observe any link between the use of FFDSP and BYHWT and stroke risk may be attributed to the
constituent differences. In practice, though these two formulae have much higher BISR influence,
they were classically used to treat a variety of vascular diseases via their stasis‐resolving and blood‐
activating influences, especially in the clinical manifestations after stroke onset [10,11].
Findings from the current study have important clinical and research implications. However,
several limitations should be noted when interpreting these results. First, coding errors are always a
possibility in an administrative database. To minimize this bias, we enrolled the subjects with the
consistent diagnoses for at least three outpatient visits or at least one inpatient admission within the
studying period. Meanwhile, it should be also remarked that the coding approach and data
availability were similar between the two groups, and this misclassification bias could have likely
been nondifferential and toward the null hypothesis, thus possibly inducing the underestimation
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rather than the overestimation of the observed estimate. Second, the LHID database does not include
detailed information regarding the predictors of stroke, especially smoking. To this end, we
performed sex‐stratified analysis, and it supported an appreciably decreased risk of stroke for AF
patients receiving CHMs, regardless of gender. Third, although our study revealed a substantial
beneficial effect of CHM use on the reduction of stroke risk among AF patients, it must be recognized
that participants were not initially randomly categorized into users and nonusers, and were only
recruited from a single country. Therefore, caution should be exerted when interpreting the findings,
especially the efficacy attributed to Chinese herbal products. Randomized controlled trials,
encompassing additional countries, are recommended to corroborate the present findings, as well as
to uncover the mechanisms underlying their successful application. These limitations
notwithstanding, this study also had considerable advantages. The database applied in this study is
representative of the entire Taiwanese population, and this large sample size ensured the obtaining
of robust findings. In addition, the retrospective 15‐year cohort study allowed us to methodically
explore the relation between CHM use and stroke in AF persons. These findings may serve as a useful
reference for future studies on this topic in other populations.
5. Conclusions
This study explored the possibility that patients with AF who receive CHMs have a reduced
subsequent risk of stroke. Although beneficial effects of CHMs on reducing stroke risk were revealed
in this study, future prospective randomized trials that overcome the limitations of this study are
needed to provide more conclusive evidence of the association suggested by the findings of this
study.
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